| Antiviral | EC50 ratio | Phenotype | Strain | Source | Marker | Assay | Reference |
|---|---|---|---|---|---|---|---|
| Ganciclovir | 6.60 | High level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Cidofovir | 18.00 | High level resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) | ||
| Foscarnet | 1.00 | No resistance | Recombinant | Details | Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. (Feb 2024) |
| Mutant | Resistances |
|---|---|
| K513E |
Ganciclovir:
|
| K513E |
Cidofovir:
|
| K513E |
Foscarnet:
|
| K513N |
Ganciclovir:
|
| K513N |
Cidofovir:
|
| K513N |
Foscarnet:
|
| K513R |
Ganciclovir:
|
| K513R |
Cidofovir:
|
| K513R |
Foscarnet:
|